Skip to Content

Ibrance Approval History

  • FDA approved: Yes (First approved February 3rd, 2015)
  • Brand name: Ibrance
  • Generic name: palbociclib
  • Dosage form: Capsules
  • Company: Pfizer Inc.
  • Treatment for: Breast Cancer

Ibrance (palbociclib) is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor for the combination treatment of ER+, HER2- metastatic breast cancer.

Development History and FDA Approval Process for Ibrance

Mar 31, 2017Approval Ibrance (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer
Feb 19, 2016Approval Pfizer Receives Expanded FDA Approval For Ibrance (palbociclib) In HR+, HER2- Metastatic Breast Cancer
Feb  3, 2015Approval FDA Approves Ibrance (palbociclib) for Postmenopausal Women with Advanced Breast Cancer
Jan  8, 2015Pfizer Provides Update on Ibrance (palbociclib)
Dec 15, 2014Pfizer Announces Palbociclib PALOMA-1 Data Published in The Lancet Oncology
Oct 13, 2014Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review
Aug 21, 2014Palbociclib Expanded Access Program Now Open To Eligible U.S. Patients With HR+, HER2- Advanced Breast Cancer
Aug 18, 2014Pfizer Announces Submission of Palbociclib New Drug Application to the FDA
May 16, 2014Pfizer To Submit Palbociclib New Drug Application With FDA Based On Final Results Of PALOMA-1

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.